AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35816479 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 129
Study 33616456 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy Slow Resistance (HSR) 90% of 1 RM
Number of subjects: 44
Study 33616456 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Slow Resistance (MSR) 55% of 1 RM
Number of subjects: 44
Study 32453454 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrimethamine + sulfonamide combinations (P-S)
Number of subjects: 0
Study 32453454 — intervention group
Group type: COMPARATOR
Intervention: Spiramycin (Spy)
Number of subjects: 0
Study 36300123 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative cell salvage (ICS)
Number of subjects: 130
Study 36300123 — intervention group
Group type: COMPARATOR
Intervention: Control (allogeneic RBC transfusion)
Number of subjects: 130
Study 35484069 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness‐Based Therapy for Insomnia (MBTI)
Number of subjects: 94
Study 35484069 — intervention group
Group type: COMPARATOR
Intervention: Sleep hygiene education and exercise program (SHEEP)
Number of subjects: 94
Study 33144141 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored recommendations
Number of subjects: 955
Study 33144141 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 955
Study 33144141 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored recommendations (men)
Number of subjects: 955
Study 33144141 — intervention group
Group type: COMPARATOR
Intervention: Control group (men)
Number of subjects: 955
Study 35841512 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application promoting preschooler's oral health
Number of subjects: 51
Study 35841512 — intervention group
Group type: COMPARATOR
Intervention: Common oral health education (educational pamphlet and verbal explanations)
Number of subjects: 51
Study 33421647 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (2 mg intravenous)
Number of subjects: 240
Study 33421647 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 240
Study 32379660 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep education and yoga intervention
Number of subjects: 17
Study 35921102 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS group (30-minute daily sessions for 4 weeks, 2 mA anodal-right and cathodal-left prefrontal stimulation)
Number of subjects: 64
Study 35921102 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS group (sham stimulation)
Number of subjects: 64
Study 35921102 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS group
Number of subjects: 64
Study 32006422 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet (2.6 g/day)
Number of subjects: 21
Study 32006422 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium sodium diet (6.0 g/day)
Number of subjects: 21
Study 32006422 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium diet (18.0 g/day)
Number of subjects: 21
Study 33524659 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor canal block (ACB)
Number of subjects: 35
Study 33524659 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline injection)
Number of subjects: 35
Study 34269813 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (1.2 g single oral dose)
Number of subjects: 263
Study 34269813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study 34269813 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 263
Study 33382736 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Protocol (CP) at PM
Number of subjects: 11
Study 33382736 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternated Protocol (AP) at PM
Number of subjects: 11
Study 33382736 — intervention group
Group type: COMPARATOR
Intervention: Continuous Protocol (CP) at AM
Number of subjects: 11
Study 33382736 — intervention group
Group type: COMPARATOR
Intervention: Alternated Protocol (AP) at AM
Number of subjects: 11
Study 34617558 — intervention group
Group type: EXPERIMENTAL
Intervention: MOS-supplemented infant formula (7.2 g MOS/L)
Number of subjects: 326
Study 32888340 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (5 mg)
Number of subjects: 115
Study 32888340 — intervention group
Group type: COMPARATOR
Intervention: Ziprasidone (10 mg)
Number of subjects: 115
Study 32888340 — intervention group
Group type: COMPARATOR
Intervention: Ziprasidone (20 mg)
Number of subjects: 115
Study 32888340 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam (2 mg)
Number of subjects: 115
Study 32888340 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 115
Study 34534196 — intervention group
Group type: EXPERIMENTAL
Intervention: Easy-to-read patient education card given at the preoperative visit
Number of subjects: 128
Study 34534196 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical counseling
Number of subjects: 128
Study 32627952 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training for 12 weeks
Number of subjects: 35
Study 32627952 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 15)
Number of subjects: 35
Study 35573181 — intervention group
Group type: EXPERIMENTAL
Intervention: Bean bag chair
Number of subjects: 14
Study 35573181 — intervention group
Group type: COMPARATOR
Intervention: Urethane chair
Number of subjects: 14
Study 33650469 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab concentration < 1.0 mg/L
Number of subjects: 91
Study 33650469 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab concentration 1.0–3.9 mg/L
Number of subjects: 91
Study 33650469 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab concentration ≥ 4.0 mg/L
Number of subjects: 91
Study 33650469 — intervention group
Group type: COMPARATOR
Intervention: Serum golimumab concentration < 1.0 mg/L
Number of subjects: 91
Study 33650469 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAbs detected
Number of subjects: 91
Study 33650469 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab concentrations ≥ 1.0 mg/L
Number of subjects: 91
Study 32832625 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized belonging intervention
Number of subjects: 1063
Study 32832625 — intervention group
Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 1063
Study 32558624 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric infusion of fructose (25g)
Number of subjects: 15
Study 32558624 — intervention group
Group type: COMPARATOR
Intervention: Water (placebo)
Number of subjects: 15
Study 32558624 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose in neutral emotion
Number of subjects: 15
Study 32558624 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose in sad emotion
Number of subjects: 15
Study 32901464 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization (TACE)
Number of subjects: 750
Study 32901464 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive models based on pre-TACE imaging findings
Number of subjects: 750
Study 36348331 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondromalacia patella (CMP)
Number of subjects: 22710
Study 36348331 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondromalacia patella (CMP) in patients over 65 years old
Number of subjects: 22710
Study 36348331 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondromalacia patella (CMP) in women
Number of subjects: 22710
Study 36348331 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without CMP)
Number of subjects: 22710
Study 33200227 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized peptide vaccination (PPV)
Number of subjects: 310
Study 33200227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study 33200227 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV
Number of subjects: 310
Study 33200227 — intervention group
Group type: COMPARATOR
Intervention: PPV and Placebo
Number of subjects: 310
Study 32182587 — intervention group
Group type: EXPERIMENTAL
Intervention: Short warm-up (8 × 100 m with gradual increase from 60% to 95% of maximal speed with 1-min rest)
Number of subjects: 14
Study 32182587 — intervention group
Group type: COMPARATOR
Intervention: Long warm-up (∼35 min at low intensity, including 5 min at moderate and 3 min at high intensity)
Number of subjects: 14
Study 32182587 — intervention group
Group type: EXPERIMENTAL
Intervention: Short warm-up
Number of subjects: 14
Study 32182587 — intervention group
Group type: COMPARATOR
Intervention: Long warm-up
Number of subjects: 14
Study 32182587 — intervention group
Group type: EXPERIMENTAL
Intervention: Test 2 (after warm-up)
Number of subjects: 14
Study 34240490 — intervention group
Group type: EXPERIMENTAL
Intervention: Care programme based on Comfort Theory
Number of subjects: 120
Study 34240490 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care
Number of subjects: 120
Study 33091549 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP+HA
Number of subjects: 122
Study 33091549 — intervention group
Group type: COMPARATOR
Intervention: PRP
Number of subjects: 122
Study 33091549 — intervention group
Group type: COMPARATOR
Intervention: PRP and PRP+HA
Number of subjects: 122
Study 33016036 — intervention group
Group type: EXPERIMENTAL
Intervention: Protopine and Nuciferine syrup, 10 ml, once a day, for 8 weeks
Number of subjects: 100
Study 33016036 — intervention group
Group type: COMPARATOR
Intervention: Placebo (flavoured coloured water), 10 ml, once a day, for 8 weeks
Number of subjects: 100
Study 35695009 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic strength training (physical exercise group, PEG)
Number of subjects: 23
Study 35695009 — intervention group
Group type: COMPARATOR
Intervention: Breathing exercises (respiratory physiotherapy group, RPG)
Number of subjects: 23
Study 33771947 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-point linear method
Number of subjects: 86
Study 33771947 — intervention group
Group type: COMPARATOR
Intervention: Multiple-point polynomial method
Number of subjects: 86
Study 33771947 — intervention group
Group type: COMPARATOR
Intervention: 2-point method
Number of subjects: 86
Study 33771947 — intervention group
Group type: COMPARATOR
Intervention: Velocity of the last repetition of a set to failure
Number of subjects: 86
Study 33771947 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual V1RM
Number of subjects: 86
Study 33771947 — intervention group
Group type: EXPERIMENTAL
Intervention: General V1RM
Number of subjects: 86
Study 32842367 — intervention group
Group type: EXPERIMENTAL
Intervention: One shot of carboplatin (76 mg/kg, i.p.)
Number of subjects: 18
Study 32842367 — intervention group
Group type: EXPERIMENTAL
Intervention: Two shots of carboplatin (76 mg/kg, i.p., one-week interval)
Number of subjects: 18
Study 32842367 — intervention group
Group type: COMPARATOR
Intervention: Control group (group A)
Number of subjects: 18
Study 34953219 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg/day
Number of subjects: 100
Study 34953219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 32320537 — intervention group
Group type: EXPERIMENTAL
Intervention: mobile high-frequency chest wall oscillation (mHFCWO)
Number of subjects: 0
Study 32320537 — intervention group
Group type: COMPARATOR
Intervention: standard nonmobile high-frequency chest wall oscillation (sHFCWO)
Number of subjects: 0
Study 34694240 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet noninvasive ventilation (NIV) with specific settings
Number of subjects: 2
Study 34694240 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake prone positioning for 6-hour sessions
Number of subjects: 2
Study 34694240 — intervention group
Group type: COMPARATOR
Intervention: High-flow nasal oxygen (HFNO)
Number of subjects: 2
Study 34694240 — intervention group
Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 2
Study 32755104 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol dose 0.06%
Number of subjects: 41
Study 32755104 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol dose 0.08%
Number of subjects: 41
Study 32755104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 34322853 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release fampridine (PR-FAM) 10-mg tablet twice daily
Number of subjects: 4646
Study 33220215 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose
Number of subjects: 0
Study 33220215 — intervention group
Group type: COMPARATOR
Intervention: Standard oral iron therapy
Number of subjects: 0
Study 35750461 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-training plus supplementation (Ex + Suppl, n=34)
Number of subjects: 70
Study 35750461 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control, n=36)
Number of subjects: 70
Study 33273328 — intervention group
Group type: EXPERIMENTAL
Intervention: NK + ART
Number of subjects: 20
Study 33273328 — intervention group
Group type: COMPARATOR
Intervention: ART
Number of subjects: 20
Study 32240469 — intervention group
Group type: EXPERIMENTAL
Intervention: I-View videolaryngoscope
Number of subjects: 0
Study 32240469 — intervention group
Group type: COMPARATOR
Intervention: McGrath Mac videolaryngoscope
Number of subjects: 0
Study 32240469 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 33684207 — intervention group
Group type: EXPERIMENTAL
Intervention: Text&Quit (T&Q)
Number of subjects: 80
Study 33684207 — intervention group
Group type: COMPARATOR
Intervention: Text4Coach (T4C)
Number of subjects: 80
Study 33684207 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 32465771 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG + conventional antimicrobial therapy
Number of subjects: 40
Study 32465771 — intervention group
Group type: COMPARATOR
Intervention: Conventional antimicrobial therapy alone
Number of subjects: 40
Study 32113628 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted RSV vaccine
Number of subjects: 1900
Study 32113628 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-collected nasal swabs
Number of subjects: 1900
Study 32113628 — intervention group
Group type: COMPARATOR
Intervention: Site-collected swabs
Number of subjects: 1900
Study 32113628 — intervention group
Group type: EXPERIMENTAL
Intervention: ARA‐RI endpoint definition
Number of subjects: 1900
Study 32113628 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analysis requiring ≥2 lower respiratory symptoms
Number of subjects: 1900
Study 36130751 — intervention group
Group type: EXPERIMENTAL
Intervention: iSupport for dementia carers
Number of subjects: 350
Study 36130751 — intervention group
Group type: COMPARATOR
Intervention: Standardised information about caring for someone with dementia (control-comparison)
Number of subjects: 350
Study 32017092 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri-containing lozenges (test group, n=36)
Number of subjects: 72
Study 32017092 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group, n=36)
Number of subjects: 72
Study 33308033 — intervention group
Group type: EXPERIMENTAL
Intervention: Black older adults
Number of subjects: 259
Study 33308033 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower mobility performance/functioning scores
Number of subjects: 259
Study 34460425 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized Nutritious Foods (SNFs)
Number of subjects: 522
Study 34460425 — intervention group
Group type: EXPERIMENTAL
Intervention: Host fecal mRNA transcripts
Number of subjects: 522
Study 34460425 — intervention group
Group type: COMPARATOR
Intervention: Lactulose:mannitol (L:M) test
Number of subjects: 522
Study 33928883 — intervention group
Group type: EXPERIMENTAL
Intervention: Deutetrabenazine (fixed-dose 12-36 mg)
Number of subjects: 514
Study 33928883 — intervention group
Group type: EXPERIMENTAL
Intervention: Deutetrabenazine (flexible-dose)
Number of subjects: 514
Study 33928883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 514
Study 32081945 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 32
Study 32081945 — intervention group
Group type: COMPARATOR
Intervention: Sham group (control)
Number of subjects: 32
Study 32081945 — intervention group
Group type: EXPERIMENTAL
Intervention: OMT
Number of subjects: 32
Study 36115192 — intervention group
Group type: EXPERIMENTAL
Intervention: Lu AF35700 10 mg
Number of subjects: 697
Study 36115192 — intervention group
Group type: EXPERIMENTAL
Intervention: Lu AF35700 20 mg
Number of subjects: 697
Study 36115192 — intervention group
Group type: COMPARATOR
Intervention: Active comparator (risperidone or olanzapine)
Number of subjects: 697
Study 36115192 — intervention group
Group type: EXPERIMENTAL
Intervention: Lu AF35700 (both doses)
Number of subjects: 697
Study 36115192 — intervention group
Group type: EXPERIMENTAL
Intervention: Lu AF35700
Number of subjects: 697
Study 33387497 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy plus S-1
Number of subjects: 1930
Study 33387497 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy alone
Number of subjects: 1930
Study 34622767 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 3617
Study 34622767 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 3617
Study 34622767 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 3617
Study 34622767 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab
Number of subjects: 3617
Study 34622767 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab
Number of subjects: 3617
Study 34622767 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 3617
Study 34622767 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 75 mg
Number of subjects: 3617
Study 34622767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3617
Study 34622767 — intervention group
Group type: EXPERIMENTAL
Intervention: All biologic agents
Number of subjects: 3617
Study 32820982 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling for 60 min between 60th and 120th minutes of dialysis (Session B)
Number of subjects: 7
Study 32820982 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling for 60 min between 150th and 210th minutes of dialysis (Session C)
Number of subjects: 7
Study 32820982 — intervention group
Group type: COMPARATOR
Intervention: Without cycling (Session A)
Number of subjects: 7
Study 33402518 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive Peripheral Magnetic Stimulation (rPMS)
Number of subjects: 41
Study 33402518 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive Peripheral Magnetic Stimulation (rPMS) plus Physiokinesiotherapy (PKT)
Number of subjects: 41
Study 32564996 — intervention group
Group type: EXPERIMENTAL
Intervention: Escape room activity
Number of subjects: 193
Study 32236417 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation-phase interventions for 6 weeks
Number of subjects: 517
Study 33185776 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhancing Dyadic Communication (EDC)
Number of subjects: 1509
Study 32014649 — intervention group
Group type: EXPERIMENTAL
Intervention: GSM900 exposure
Number of subjects: 60
Study 32014649 — intervention group
Group type: EXPERIMENTAL
Intervention: TETRA exposure
Number of subjects: 60
Study 32014649 — intervention group
Group type: COMPARATOR
Intervention: Control (sham exposure)
Number of subjects: 60
Study 33641712 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management intervention
Number of subjects: 24
Study 33641712 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 24
Study 33198070 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge and attitude towards retrograde peri-implantitis (RPI)
Number of subjects: 475
Study 33198070 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition of radiographic representation of RPI
Number of subjects: 475
Study 33198070 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment modality for RPI
Number of subjects: 475
Study 33198070 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of management strategies for RPI
Number of subjects: 475
Study 36438075 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) plus low-dose aspirin treatment (Group A = 85)
Number of subjects: 173
Study 36438075 — intervention group
Group type: COMPARATOR
Intervention: Low-dose aspirin treatment only (Group B = 88)
Number of subjects: 173
Study 36438075 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis for polycystic ovary syndrome (PCOS) patients
Number of subjects: 173
Study 36438075 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) plus low-dose aspirin treatment (Group A)
Number of subjects: 173
Study 33307444 — intervention group
Group type: EXPERIMENTAL
Intervention: High social isolation
Number of subjects: 642
Study 33307444 — intervention group
Group type: COMPARATOR
Intervention: Low social isolation
Number of subjects: 642
Study 33307444 — intervention group
Group type: EXPERIMENTAL
Intervention: Social isolation
Number of subjects: 642
Study 36357551 — intervention group
Group type: EXPERIMENTAL
Intervention: Video modeling technique (watched the video before the consultation)
Number of subjects: 20
Study 36357551 — intervention group
Group type: COMPARATOR
Intervention: Control group (did not watch the video before the consultation)
Number of subjects: 20
Study 34424549 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroctone olamine (PO) containing shampoo
Number of subjects: 0
Study 34424549 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroctone olamine (PO) containing leave-on treatment
Number of subjects: 0
Study 34424549 — intervention group
Group type: COMPARATOR
Intervention: Placebo formulations
Number of subjects: 0
Study 32022904 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive fluid therapy regimen
Number of subjects: 100
Study 32022904 — intervention group
Group type: COMPARATOR
Intervention: Standard management
Number of subjects: 100
Study 35504165 — intervention group
Group type: EXPERIMENTAL
Intervention: Krill oil supplementation (4g/day) for 6 months
Number of subjects: 102
Study 35504165 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 102
Study 33186729 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal Fentanyl (INF)
Number of subjects: 21
Study 33186729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21